查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球营运商筛检市场
市场调查报告书
商品编码
1380420

2023-2030 年全球营运商筛检市场

Global Carrier Screening Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

预计全球带因者筛检市场在预测期内（2023-2030）将以 17.1% 的CAGR成长。市场的成长归因于综合测试的发展。 FirstGene 4 合 1 产前筛检测试的推出是改善携带者筛检和产前护理的更广泛努力的一部分。为了满足整个怀孕期间对整体遗传见解不断增长的需求，这项涵盖产前健康和遗传学多个方面的综合测试正在帮助推动全球携带者筛检市场。例如，2023 年 1 月，针对女性健康、肿瘤业务推出了 2023 年亮点产品。这家总部位于盐湖城的公司继续做好准备，在第三季度推出FirstGene 4 合1 产前筛检测试，涵盖无创产前筛检、携带者筛检、胎儿隐性状态和胎儿-母体血液相容性。

细分市场前景

全球携带者筛检市场按类型、医疗状况、技术和最终用户进行细分。根据类型，市场被细分为扩展疾病和目标疾病。依医疗状况，市场分为血液疾病、肺病、神经病变等。根据技术，市场细分为 DNA 定序、聚合酶炼式反应 (PCR)、微阵列等。此外，根据最终用户，市场细分为医院和诊所、参考实验室、政府和公共卫生项目等。 DNA 定序子类别预计将占据技术领域的很大一部分市场份额。这是由于人类对遗传性疾病的脆弱性增加。除了基因检测知识的增加之外，由于该技术的使用增加，而不是任何道德问题，预计该市场也会成长。

预计血液学细分市场将在全球携带者筛检市场中占据相当大的份额

在医疗领域，血液学细分领域预计将在全球带因者筛检市场中占据相当大的份额。此细分市场的成长归因于对先进诊断工具的需求不断增长。 Yumizen H500 和 H550 分析仪证明了诊断技术不断发展，反映了医疗保健领域对更复杂、更有效的诊断工具日益增长的需求。由于血液分析仪的出现，血液学检测过程应该变得更快、更准确，从而增强患者护理。例如，2022 年 7 月，HORIBA Medical 在其 Yumizen H500 和 H550 血液学产品系列中推出了新产品，即便携式桌上型血液分析仪，具有改进的功能、新的功能和额外的优势。新型 Yumizen H500 和 H550 的吞吐量为每小时 60 次测试、40 个自动试管、连续加载、紧急手动模式以及透过多个分析模型和采样运行样品，旨在提供即时、全面的血液学报告。

区域展望

全球携带者筛检市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本） 、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于囊性纤维化等遗传性疾病的高盛行率、市场参与者的增加以及该地区提供的检测数量的大幅增加，预计北美将在全球市场中占据显着份额。地区。

预计亚太地区全球带因者筛检市场将以显着的CAGR成长

在所有地区中，亚太地区预计在预测期内将以相当大的CAGR成长。区域增长归因于该地区对基因检测的需求和公众意识的不断增长。携带者筛检方法的出现以及公众对遗传疾病的认识不断提高，提高了对基因检测服务，特别是携带者筛检的需求。根据 BMC Medical Genetics 的数据，2022 年 11 月，出生缺陷是从出生时就存在的异常，可能导致严重死亡率、生产力下降和生活品质下降。在发展中国家，由于免疫接种、腹泻和呼吸道感染控制以及医疗保健改善等传染性和营养原因的减少，胎儿、新生儿、婴儿和儿童死亡率的比例不断上升。在西方，出生缺陷占早期死亡率的 29.8%，占慢性病的 29.2%。在印度，2010-2013年抽样登记系统调查报告称，先天畸形和遗传性疾病分别占儿童死亡率、婴儿死亡率和新生儿死亡率的4.4%、4.6%和4.0%。预防出生缺陷，包括遗传性疾病，是所有国家的优先事项，因为它们会造成社会耻辱、经济负担并降低生活品质，特别是在资源匮乏的国家。

市场参与者展望

服务全球携带者筛检市场的主要公司包括： Congenica Ltd、Illumina, Inc.、Invitae Corp.、Myriad Genetics, Inc.、Natera Inc.等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2022 年1 月，Congenica 在2022 年阿拉伯健康大会上推出了一项新开发的行业首创产品，该产品结合了潜在父母的数位基因图谱，进行彻底的携带者筛检，以支持计划生育决策。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球营运商筛选市场的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • DiaSorin SpA
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Eurofins Scientific
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Fulgent Genetics, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按类型分類的全球营运商筛选市场
    • 扩大携带者筛检
    • 针对性疾病带因者筛检
  • 按医疗状况分類的全球携带者筛检市场
    • 血液学状况
    • 肺部疾病
    • 神经系统疾病
    • 其他（家族性地中海热 (FMF) 和脆性 X 综合征）
  • 按类型分類的全球营运商筛选市场
    • DNA定序
    • 聚合酶炼式反应 (PCR)
    • 微阵列
    • 其他（次世代定序 (NGS)、筛选条件和直接面向消费者的测试）
  • 按最终用户分類的全球营运商筛选市场
    • 医院和诊所
    • 参考实验室
    • 政府和公共卫生计划
    • 其他（製药和生物型公司）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Ambry Genetics Corp.
  • Cepheid
  • Congenica Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Invitae Corp.
  • Laboratory Corporation of America (Labcorp)
  • MedGenome Inc
  • Myriad Genetics, Inc.
  • Natera Inc.
  • PerkinElmer AES
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific
Product Code: OMR2027829

Title: Global Carrier Screening Market Size, Share & Trends Analysis Report by Type (Expanded Carrier Screening, and Targeted Disease Carrier Screening), by Medical Condition (Hematological, Pulmonary, Neurological, and Others), by Technology (DNA Sequencing, Polymerase Chain Reaction (PCR), Microarrays, and Others), and by End User (Hospitals and Clinics, Reference Laboratories, Government and Public Health Programs, and Others)Forecast Period (2023-2030).

The global carrier screening market is anticipated to grow at a CAGR of 17.1% during the Forecast Period (2023-2030). The market's growth is attributed to development of comprehensive testing. The availability of the FirstGene 4-in-1 prenatal screening test is part of a wider effort to improve carrier screening and prenatal care. In response to the rising need for holistic genetic insights throughout pregnancy, this comprehensive test, that covers several aspects of prenatal health and genetics, is helping to boost the global carrier screening market. For instance, in January 2023, Highlights 2023 Product Launched for Women's Health, Oncology Businesses. The Salt Lake City-based company continues to grow prepared to introduce its FirstGene 4-in-1 prenatal screening test, that covers noninvasive prenatal screening, carrier screening, fetal recessive status, and feto-maternal blood compatibility, in Q3.

Segmental Outlook

The global carrier screening market is segmented on the type, medical condition, technology, and end-user. Based on the type, the market is sub-segmented into expanded, and targeted disease. Based on the medical condition, the market is sub-segmented into hematological, pulmonary, neurological, and others. Based on the technology, the market is sub-segmented into DNA sequencing, polymerase chain reaction (PCR), microarrays, and others. Further, on the basis of end-user, the market is sub-segmented into hospitals and clinics, reference laboratories, government and public health programs, and others. The DNA sequencing subcategory is expected to capture a significant portion of the market share within the technology segment. This is attributed to the increase in humanity's vulnerability to genetic disorders. The market is also anticipated to rise as a result of increased uses for the technology in addition to increased knowledge of genetic testing instead of any ethical problems.

The Hematological Sub-Segment is Anticipated to Hold a Considerable Share of the Global Carrier Screening Market

Among the medical condition, the hematological sub-segment is expected to hold a considerable share of the global carrier screening market. The segmental growth is attributed to the growing demand for advanced diagnostic tools. The Yumizen H500 & H550 analyzers are proof of the continuously evolving diagnostic technology that reflects the growing demand for more sophisticated and effective diagnostic tools in the healthcare sector. The hematological testing process should become faster and more accurate owing to blood analyzers, that can enhance patient care. For instance, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the portable benchtop hematology analyzers with improved functionality, new capabilities, and additional advantages. With a throughput of 60 tests per hour, 40 tubes of autonomy with continuous loading, urgent manual mode, and running samples through several analytical models and sampling, the new Yumizen H500 & H550 have been intended to offer an immediate and thorough hematological report.

Regional Outlook

The global carrier screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to a high prevalence of genetic disorders such as cystic fibrosis, a rise in market participants, and a significant rise in the number of tests offered in the region.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Carrier Screening Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for genetic testing and public awareness across the region. The availability of carrier screening methods and growing public awareness of genetic diseases have raised demand for genetic testing services, especially carrier screening. According to the BMC Medical Genetics, in November 2022, birth defects are abnormalities that are present from birth and can cause significant mortality, reduced productivity, and diminished quality of life. In developing countries, they have contributed to an increasing proportion of fetal, neonatal, infant and childhood mortality owing to a decline in infectious and nutritional causes such as immunizations, control of diarrheal and respiratory infections, and improved healthcare. In the West, birth defects account for 29.8% of early mortality and 29.2% of chronic problems. In India, the Sample Registration System Survey during 2010-2013 reported that congenital malformations and genetic disorders contributed 4.4, 4.6 and 4.0% to childhood mortality, infant mortality and neonatal mortality, respectively. The prevention of birth defects, including genetic disorders, is a priority in all countries, as they cause social stigmatization, economic burden, and diminish quality of life, especially in resource-poor countries.

Market Players Outlook

The major companies serving the global carrier screening market include: Congenica Ltd, Illumina, Inc., Invitae Corp., Myriad Genetics, Inc., Natera Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2022, Congenica, launched a newly developed, industry-first offering at Arab Health 2022 that combines the digital genetic profiles of both potential parents for thorough carrier screening to support family planning decisions.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global carrier screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. DiaSorin S.p.A.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Eurofins Scientific
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Fulgent Genetics, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Carrier Screening Market by Type
    • 4.1.1. Expanded Carrier Screening
    • 4.1.2. Targeted Disease Carrier Screening
  • 4.2. Global Carrier Screening Market by Medical Condition
    • 4.2.1. Hematological Conditions
    • 4.2.2. Pulmonary Conditions
    • 4.2.3. Neurological Conditions
    • 4.2.4. Others (Familial Mediterranean Fever (FMF), and Fragile X Syndrome)
  • 4.3. Global Carrier Screening Market by Type
    • 4.3.1. DNA Sequencing
    • 4.3.2. Polymerase Chain Reaction (PCR)
    • 4.3.3. Microarrays
    • 4.3.4. Others (Next-Generation Sequencing (NGS), Screened Conditions, and Direct-to-Consumer Testing)
  • 4.4. Global Carrier Screening Market by End-User
    • 4.4.1. Hospitals and clinics
    • 4.4.2. Reference Laboratories
    • 4.4.3. Government and Public Health Programs
    • 4.4.4. Others (Pharmaceutical and Biotype Companies)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Ambry Genetics Corp.
  • 6.2. Cepheid
  • 6.3. Congenica Ltd.
  • 6.4. F. Hoffmann-La Roche Ltd.
  • 6.5. Illumina, Inc.
  • 6.6. Invitae Corp.
  • 6.7. Laboratory Corporation of America (Labcorp)
  • 6.8. MedGenome Inc
  • 6.9. Myriad Genetics, Inc.
  • 6.10. Natera Inc.
  • 6.11. PerkinElmer AES
  • 6.12. Quest Diagnostics Inc.
  • 6.13. Thermo Fisher Scientific

LIST OF TABLES

  • 1. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL EXPANDED CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL TARGETED DISEASE CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CARRIER SCREENING FOR HEMATOLOGICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CARRIER SCREENING FOR PULMONARY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CARRIER SCREENING FOR NEUROLOGICAL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CARRIER SCREENING FOR OTHER MEDICAL CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 10. GLOBAL CARRIER SCREENING BY DNA SEQUENCING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CARRIER SCREENING BY POLYMERASE CHAIN REACTION (PCR) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CARRIER SCREENING BY MICROARRAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CARRIER SCREENING BY OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 15. GLOBAL CARRIER SCREENING IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL CARRIER SCREENING IN REFERENCE LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL CARRIER SCREENING IN GOVERNMENT AND PUBLIC HEALTH PROGRAMS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL CARRIER SCREENING IN OTHER END USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 28. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 29. EUROPEAN CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY MEDICAL CONDITION, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD CARRIER SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CARRIER SCREENING MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL EXPANDED CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL TARGETED DISEASE CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CARRIER SCREENING MARKET SHARE BY MEDICAL CONDITION, 2022 VS 2030 (%)
  • 5. GLOBAL CARRIER SCREENING FOR HEMATOLOGICAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CARRIER SCREENING FOR PULMONARY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CARRIER SCREENING FOR NEUROLOGICAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CARRIER SCREENING MARKET FOR OTHER APPLICATIONS SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CARRIER SCREENING MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 10. GLOBAL CARRIER SCREENING BY DNA SEQUENCING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CARRIER SCREENING BY POLYMERASE CHAIN REACTION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CARRIER SCREENING BY MICROARRAYS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CARRIER SCREENING BY OTHER TECHNOLOGIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CARRIER SCREENING MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 15. GLOBAL CARRIER SCREENING IN HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL CARRIER SCREENING IN REFERENCE LABORATORIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CARRIER SCREENING IN GOVERNMENT AND PUBLIC HEALTH PROGRAMS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL CARRIER SCREENING IN OTHER END USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL CARRIER SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 20. US CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CARRIER SCREENING MARKET SIZE, 2022-2030 ($ MILLION)